A randomised, double-blind, crossover study to compare the effects of exenatide and sitagliptin on postprandial glucose in subjects with type 2 diabetes mellitus
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2015
At a glance
- Drugs Exenatide (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 09 Sep 2008 Primary and secondary endpoint results presented at EASD 2008 according to Amylin Pharmaceuticals media release.
- 01 Apr 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 07 Nov 2007 The expected completion date for this trial is now 1 Jan 2008.